Research Spotlight - Radioimmunotherapy: Optimizing delivery to solid tumors

Therapeutic Delivery

Volumn 2, Issue 5, 2011, Pages 567-572

  Rajkumar, Vineeth ^a   Dearling, Jason L ^b   Packard, Alan ^b   Pedley, R Barbara ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

colorectal adenocarcinoma; radioimmunotherapy; tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY A5B7 I 131; COMBRETASTATIN A4 PHOSPHATE; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L19 SIP I 131; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VADIMEZAN; YTTRIUM 90;

ANTIBODY STRUCTURE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CARCINOMA; DRUG RESPONSE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR MICROENVIRONMENT; COLORECTAL TUMOR; METHODOLOGY;

COLORECTAL NEOPLASMS; HUMANS; RADIOIMMUNOTHERAPY; RESEARCH DESIGN; TUMOR MICROENVIRONMENT;

EID: 79956103070     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.33     Document Type: Article

References (28)

1. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q. J. Nucl. Med. Mol. Imaging 50(4), 248-264 (2006). (Pubitemid 46157607)
2. Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. Update of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group. Ann. Surg. Oncol. 14(9), 2577-2590 (2007). (Pubitemid 47389553)
3. Dearling JL, Pedley RB. Technological advances in radioimmunotherapy. Clin. Oncol. (R. Coll. Radiol.) 19(6), 457-469 (2007). (Pubitemid 46995619)
4. Sharma SK, Pedley RB. Xenograft mouse models for tumour targeting. In:Antibody Engineering Vol. 2. Kontermann R, DübelS (Eds). Springer-Verlag Berlin Heidelberg, NY, USA 477-490 (2010).
5. Dearling JLJ, Pedley RB. Antibody directed radioisotope therapy. In:Radiotherapy in Practice: Volume III Radioisotopes. Hoskin PJ (Ed.). Oxford University Press, Oxford, UK 9-45 (2007)
6. Flynn AA, Boxer GM, Begent RH, Pedley RB. Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol. Immunother. 50(2), 77-81 (2001). (Pubitemid 32424491)
7. Flynn AA, Pedley RB, Green AJ et al. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. Int. J. Radiat. Biol. 78(5), 407-415 (2002). (Pubitemid 34496891)
8. Flynn AA, Green AJ, Pedley RB et al. A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer 94(Suppl. 4), 1249-1257 (2002). (Pubitemid 34150886)
9. Pedley RB, El-Emir E, Flynn AA et al. Synergy between vascular targeting agents and antibody-directed therapy. Int. J. Radiat. Oncol. Biol. Phys. 54(5), 1524-1531 (2002). (Pubitemid 35380059)
10. Dearling JL, Flynn AA, Qureshi U et al. Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: Influence of tumor size and location within host organ on antibody uptake. Nucl. Med. Biol. 36(8), 883-894 (2009).
11. El-Emir E, Qureshi U, Dearling JL et al. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res. 67(24), 11896-11905 (2007).
12. Fidarova EF, El-Emir E, Boxer GM et al. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: Implications for radioimmunotherapy. Clin. Cancer Res. 14(9), 2639-2646 (2008).
13. Flynn AA, Green AJ, Boxer GM, Casey JL, Pedley RB, Begent RH. A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. Int. J. Radiat. Oncol. Biol. Phys. 43(1), 183-189 (1999). (Pubitemid 29065843)
14. Flynn AA, Pedley RB, Green AJ, Boxer GM, Boden R, Begent RH. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images. Cancer Biother. Radiopharm. 16(5), 391-400 (2001). (Pubitemid 33151116)
15. Flynn AA, Pedley RB, Green AJ et al. Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: A comparative study using the linear - quadratic formulation. Int. J. Radiat. Biol. 77(4), 507-517 (2001). (Pubitemid 32281131)
16. Folarin AA, Konerding MA, Timonen J, Nagl S, Pedley RB. Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography. Microvasc. Res. 80(1), 89-98 (2010).
17. Zhang EZ, Laufer JG, Pedley RB, Beard PC. In vivo high-resolution 3D photoacoustic imaging of superficial vascular anatomy. Phys. Med. Biol. 54(4), 1035-1046 (2009).
18. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4(10), 806-813 (2004). (Pubitemid 39331152)
19. Violet JA, Dearling JL, Green AJ, Begent RH, Pedley RB. Fractionated 131I anti-CEA radioimmunotherapy: Effects on xenograft tumour growth and haematological toxicity in mice. Br. J. Cancer 99(4), 632-638 (2008).
20. Pedley RB, Hill SA, Boxer GM et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 61(12), 4716-4722 (2001). (Pubitemid 32691881)
21. El-Emir E, Boxer GM, Petrie IA et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur. J. Cancer 41(5), 799-806 (2005). (Pubitemid 40342562)
22. Pedley RB, Begent RH, Boden JA, Boxer GM, Boden R, Keep PA. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model. Int. J. Cancer 57(6), 830-835 (1994). (Pubitemid 24216819)
23. Pedley RB, Boden JA, Boden R et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 56(14), 3293-3300 (1996). (Pubitemid 26242979)
24. Pedley RB, Sharma SK, Boxer GM et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 59(16), 3998-4003 (1999). (Pubitemid 29393568)
25. Beauregard DA, Pedley RB, Hill SA, Brindle KM. Differential sensitivity of two adenocarcinoma xenografts to the antivascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4- acetic acid, assessed using MRI and MRS. NMR Biomed. 15(2), 99-105 (2002). (Pubitemid 34213399)
26. Pedley RB, Tozer GM. The use of animal models in the assessment of vascular disrupting agents (VDAs). In:Vascular Disruptive Agents for the Treatment of Cancer. Tim Mayer (Ed.). Springer, NY, USA 49-75 (2010).
27. El-Emir E, Dearling JL, Huhalov A et al. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br. J. Cancer 96(12), 1862-1870 (2007). (Pubitemid 46912019)
28. Meyer T, Gaya AM, Dancey G et al. A Phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4- phosphate in advanced gastrointestinal carcinomas. Clin. Cancer Res. 15(13), 4484-4492 (2009).